Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows
The fear started in 1941 with a researcher named Charles Huggins, who was studying men with advanced, metastatic prostate cancer and noticed something that seemed obvious at the time: when you removed the source of testosterone by castrating these men, their cancer markers dropped, and when you injected testosterone back into those castrated men, the markers came back up.
Huggins won the Nobel Prize for that observation, and the medical community drew a clean line from it: testosterone feeds prostate cancer, so more testosterone must be dangerous.
That conclusion held for nearly 80 years.
Here is what was actually correct about that logic. In men whose testosterone has been surgically removed and dropped to near zero, injecting testosterone does reactivate prostate cancer activity. That part is real. The problem is that this observation applies to a very specific situation, castrated men going from zero to something, and the medical community applied it to every situation, including healthy men on TRT whose testosterone was never near zero to begin with.
Understanding why that generalization breaks down requires understanding something called androgen receptor saturation, which is the point at which the prostate has used up all available binding sites for testosterone and adding more testosterone produces no additional effect.
Think of it like a parking lot. If the lot is empty, every car you add fills a new space and changes what the lot looks like. But once the lot is full, more cars arriving outside do not change anything inside.
Research published in the European Urology journal identified that saturation point at around 240 to 250 nanograms per deciliter. Below that threshold, changes in testosterone have a dramatic and measurable effect on prostate tissue. Above it, the prostate is effectively full and additional testosterone has nowhere to go.
A man with low testosterone sitting at 180 ng/dL who starts TRT and brings his levels to 600 ng/dL is not giving his prostate 420 points worth of new stimulation. He is moving from below the saturation threshold to well above it, crossing through the zone where changes matter and landing in a range where the prostate has already hit its ceiling.
That is the mechanism the 1941 research never captured, because the experiment was designed to move men from complete androgen deprivation back up, which means it was testing exactly the zone below 250, where testosterone does have a real effect.
When researchers ran actual prospective trials on men using TRT at normal therapeutic levels, the results do not support the original conclusion.
The largest randomized trial on this question followed 5,204 men with diagnosed hypogonadism for an average of 33 months and compared prostate cancer incidence between those receiving testosterone and those receiving a placebo. Prostate cancer occurred in 0.46 percent of the testosterone group and 0.42 percent of the placebo group, which is a hazard ratio of 1.07 with a p-value of 0.87, meaning there is no statistically meaningful difference between the two groups.
A Finnish population study tracking 78,615 men over 18 years found something that goes further in the other direction: men using TRT had a prostate cancer specific mortality that was actually lower, with a hazard ratio of 0.52 compared to non-users.
A 2024 meta-analysis pooling 28 randomized controlled trials measured PSA change, which is a blood marker used to track prostate health, and found that TRT raised PSA by an average of 0.08 nanograms per milliliter. That number is not statistically significant and is not clinically meaningful given that normal PSA fluctuations within a person across tests are typically far larger than that.
The most direct challenge to the original fear came from a study that asked what happens when you give testosterone to men who already have prostate cancer. Among 69,984 men who had received definitive treatment for localized prostate cancer, 1,012 of them went on to receive TRT. Researchers found no increase in recurrence and no increase in death.
If testosterone cannot accelerate an existing cancer that is already present in the body, the argument that it causes new cancers in healthy men becomes very difficult to sustain.
The monitoring protocol that makes sense given all of this is straightforward. Get a baseline PSA before starting TRT, check it again at three to six months into treatment, and then measure it annually. The Endocrine Society's clinical practice guidelines define a PSA rise of more than 1.4 nanograms per milliliter above your individual baseline as the threshold for a urology referral. That threshold is not about TRT being inherently risky, it is about making sure that if something is going on in the prostate, whether related to TRT or not, it gets caught early.
The irony buried in 80 years of this fear is that the original 1941 experiment was not wrong about what it measured. It was wrong about what it meant. Huggins accurately observed that testosterone reactivates prostate cancer in castrated men, and that finding has real clinical relevance in androgen deprivation therapy, which is still used today to treat advanced prostate cancer by dropping testosterone to castrate levels.
But somewhere in the translation from "testosterone matters when it moves from zero to something" to "testosterone causes cancer in normal men," the mechanism got lost, and the conclusion outlived the evidence it was actually based on.
The data we have now, from five thousand person trials to eighteen year population studies to research on men with existing cancer, points in one direction, and that direction is not what the Nobel Prize suggested.
References
- Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
- Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
- Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
- Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
- Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
- Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
- Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.